Profil
Douglas Hanahan is the founder of Opna Bio SA. His current job(s) include being the Director at Opna-IO LLC and Opna Immuno-Oncology SA.
Postes actifs de Douglas Hanahan
| Sociétés | Poste | Début |
|---|---|---|
Opna-IO LLC
 Opna-IO LLC Miscellaneous Commercial ServicesCommercial Services Opna-IO LLC provides biotechnology services. The company is headquartered in New York, NY. | Directeur/Membre du Conseil | - |
Opna Immuno-Oncology SA
 Opna Immuno-Oncology SA BiotechnologyHealth Technology Opna Immuno-Oncology SA is a Swiss biotechnology company that focuses on researching and developing biotechnology products. The private company is based in Saint-Sulpice, Switzerland. | Directeur/Membre du Conseil | - |
Opna Bio SA
 Opna Bio SA Pharmaceuticals: GenericHealth Technology Opna Bio is a clinical-stage biopharmaceutical company located in the US that focuses on discovering and developing novel oncology therapeutics. Opna's lead clinical compound, opn-2853, a bromo and extra terminal (bet) domain inhibitor, is currently in a phase 1/2 trial with ruxolitinib (jakafi®) in myelofibrosis, a chronic bone marrow disorder. The American company's team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market. The company has a broad portfolio that targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-x mental retardation protein (fmrp) and a diversified pipeline of validated oncology assets acquired from plexxikon. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Opna-IO LLC
Opna-IO LLC Miscellaneous Commercial ServicesCommercial Services Opna-IO LLC provides biotechnology services. The company is headquartered in New York, NY. | Commercial Services |
Opna Immuno-Oncology SA
Opna Immuno-Oncology SA BiotechnologyHealth Technology Opna Immuno-Oncology SA is a Swiss biotechnology company that focuses on researching and developing biotechnology products. The private company is based in Saint-Sulpice, Switzerland. | Health Technology |
Opna Bio SA
Opna Bio SA Pharmaceuticals: GenericHealth Technology Opna Bio is a clinical-stage biopharmaceutical company located in the US that focuses on discovering and developing novel oncology therapeutics. Opna's lead clinical compound, opn-2853, a bromo and extra terminal (bet) domain inhibitor, is currently in a phase 1/2 trial with ruxolitinib (jakafi®) in myelofibrosis, a chronic bone marrow disorder. The American company's team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market. The company has a broad portfolio that targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-x mental retardation protein (fmrp) and a diversified pipeline of validated oncology assets acquired from plexxikon. | Health Technology |